Scott Brun, MD, has over twenty five years of drug development and leadership experience in the pharmaceutical industry. His leadership positions include Corporate Vice President of Scientific Affairs at AbbVie and Head of AbbVie Ventures, a corporate venture fund responsible for investment opportunities within AbbVie’s R&D therapeutic areas as well as technology platforms of interest. Previously, Dr. Brun served as Corporate Vice President and Head of Pharmaceutical Development (Chief Medical Officer) at AbbVie. During his tenure, Dr. Brun led a global organization with responsibilities for AbbVie’s portfolio of early and late stage pipeline compounds as well as marketed compounds within oncology, neurology, immunology, renal, infectious disease, and women’s and men’s health. Dr. Brun contributed to the development and approval of a number of products across therapeutic areas, including Kaletra, Viekira, Mavyret, Venclexta, Rinvoq, Skyrisi, Duopa, and Orilissa. Prior to joining AbbVie, Dr. Brun spent over 15 years at Abbott Laboratories, where he held positions of increasing leadership in drug development within the R&D organization.

Dr. Brun is currently acting as an independent consultant and advisor to the venture capital and biopharmaceutical industry. He is a venture partner at the global life science VC firm Abingworth (part of The Carlyle Group), a senior medical advisory to Launch Therapeutics, a board member at Axial Therapeutics, Trishula Therapeutics, Jasper Therapeutics, Forte Bio, and Cabaletta Bio, and a consultant to a range of startup companies and academic incubator programs. He acted as a senior R&D/business development advisor to Horizon Therapeutics prior to the company’s acquisition by Amgen.

Dr. Brun received his BS in Biochemistry from the University of Illinois at Urbana-Champaign and earned his MD from the Johns Hopkins University School of Medicine. He completed his residency in ophthalmology at the Massachusetts Eye and Ear Infirmary/Harvard Medical School.